The European Cancer Congress 2015

login
My congress planner
close
Forgot password

Create account

Searchable Programme for ECC2015

Keyword / Author:
  • 26
    SAT
    10:25 – 12:35
    Abstract nr
    Early Drug Development

    Proffered Paper Session: Early Drug Development I

    Chair: J.C. Soria (France)

    Chair: J.H. Schellens (Netherlands)

    10:25
    300
    Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma
    Speaker: D. Rasco (USA)
    Display abstract

    10:40
    301
    First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
    Speaker: A. Azaro (Spain)
    Display abstract

    10:55
    302
    A phase 1 study of EPZ-6438 (E7438), an Enhancer of Zeste-Homolog 2 (EZH2) inhibitor: Preliminary activity in INI1-negative tumors
    Speaker: A. Italiano (France)
    Display abstract

    11:10
    Discussant : E. Raymond (Switzerland)

    11:20
    303
    A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors
    Speaker: V. De Weger (Netherlands)
    Display abstract

    11:35
    304
    Vanucizumab reduces vessel permeability, perfusion and cellular density of tumor lesions in cancer patients as measured by DCE-MRI and DW-MRI
    Speaker: T. Nayak (Switzerland)
    Display abstract

    11:50
    305
    Influencing sorafenib disposition by blocking hepatocellular sorafenib-glucuronide uptake with rifampin in mice and humans
    Speaker: S. Bins (Netherlands)
    Display abstract

    12:05
    Discussant : R. Plummer (United Kingdom)

    12:15
    12LBA
    LATE BREAKING ABSTRACT: Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé Program
    Speaker: G. Vassal (France)
    Display abstract

    12:25
    Discussant : K. Kerr (United Kingdom)

  • 27
    SUN
    08:00 – 08:45
    Early Drug Development

    Teaching Lecture: Use of the Preoperative Window for Early Drug Development

    Chair: R. Plummer (United Kingdom)

    Speaker: H.H. Zwierzina (Austria)

  • 27
    SUN
    09:00 – 10:30
    Early Drug Development

    Scientific Symposium: New Drugs on the Horizon I

    Chair: J.H. Schellens (Netherlands)

    Co-Chair: W. Eberhardt (Germany)
    Display Presentation Details

    09:00
    Melanoma: Immunotherapy, TKIs, chemotherapy, combinations? What’s next?
    Speaker: C. Blank (Netherlands)
    Display Presentation Details

    09:25
    Lung cancer: New targets, new drugs, will we eventually even improve survival?
    Speaker: M. O’Brien (United Kingdom)
    Display Presentation Details

    09:50
    Myelodysplastic syndrome: The epigenetic model for drug development?
    Speaker: G. Garcia-Manero (USA)
    Display Presentation Details

    Discussion & Roundup

  • 27
    SUN
    11:30 – 12:30
    Early Drug Development

    Special Session: Reducing the Size of the Drug Development Graveyard

    Chair: C. Vens (Netherlands)

    11:30
    Considering resistance mechanisms and genetic tumour context
    Speaker: R. Bernards (Netherlands)
    Display Presentation Details

    11:45
    Drug development approaches and inconsistencies in pharmacogenomics studies
    Speaker: J. Quackenbush (USA)

    12:00
    Good drugs, bad trials
    Speaker: R. Plummer (United Kingdom)
    Display Presentation Details

    Discussion

  • 27
    SUN
    15:15 – 16:15
    Early Drug Development

    Debate: This House Believes that Single Agent Activity Is Required for Development in Combination Therapy

    Moderator: R. Salazar (Spain)

    15:15
    Speaker in favour: T. Yap (United Kingdom)

    15:30
    Speaker against: J.H. Schellens (Netherlands)

    15:45
    Seconder in favour: J.C. Soria (France)

    15:55
    Seconder against: A. Chalmers (United Kingdom)

    Discussion & Voting

Print all results list